Levetiracetam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Levetiracetam: From Epilepsy to Visual Epilepsy
One-Sentence Summary
Levetiracetam is a widely used second-generation antiepileptic drug, established globally for partial-onset seizures (with or without secondary generalisation) and other seizure types. The TxGNN model predicts it may also be effective for Visual Epilepsy (a photosensitive/reflex epilepsy subtype), with 9 clinical trials and 20 publications currently identified in this evidence pack — though none directly and specifically studies visual/photosensitive epilepsy as the primary endpoint.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy — partial-onset seizures, with adjunctive use in myoclonic and primary generalised tonic-clonic seizures (established global indication per literature in this evidence pack; no Australian ARTG/PI text available — see Market Status) |
| Predicted New Indication | Visual Epilepsy |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 (preclinical/mechanistic; no controlled trials specific to visual epilepsy) |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Research Question (Decision Stage S1) |
Why is This Prediction Reasonable?
Detailed, Australia-specific mechanism-of-action documentation is not available in this evidence pack (flagged as a High-severity data gap, DG002 — recommended remediation: query DrugBank API). Based on the literature captured here, levetiracetam is an established second-generation antiepileptic drug that binds synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and broadly dampening cortical hyperexcitability. It is approved worldwide as adjunctive and monotherapy treatment of partial-onset seizures, and as adjunctive treatment of myoclonic seizures in juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures.
Visual epilepsy (photosensitive/reflex epilepsy) is thought to arise from excessive occipital cortical excitability triggered by visual stimuli — mechanistically the same broad category of cortical hyperexcitability that levetiracetam’s SV2A-mediated action is designed to suppress. This provides biological plausibility for the TxGNN prediction.
However, the rationale supplied with this candidate is explicit that the supporting evidence is indirect: all 9 clinical trials and 20 publications identified relate to general epilepsy, status epilepticus, or neonatal seizures, and none specifically enrolled or studied patients with visual/photosensitive epilepsy. The prediction should therefore be read as mechanistically plausible but clinically unproven for this specific indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT04559529 | Phase 2 | Completed | 62 | Tests whether levetiracetam reduces hippocampal hyperactivity in psychotic disorders using fMRI during a visual scene-processing task; not a visual-epilepsy efficacy trial. |
| NCT03107507 | Phase 4 | Unknown | 40 | Efficacy of levetiracetam in control of neonatal seizures (general seizure population). |
| NCT00855738 | Phase 4 | Completed | 111 | Liceo Study — observational effectiveness of newer AEDs (including levetiracetam) as first bitherapy in focal epilepsy. |
| NCT04833907 | Phase 1/2 | Enrolling by invitation | 24 | AVASPA gene therapy trial for Canavan disease; levetiracetam relevance is incidental/background rather than a study intervention. |
| NCT04573803 | Phase 3 | Not yet recruiting | 1649 | MAST trial — optimal duration/agent (phenytoin vs levetiracetam) for seizure prophylaxis after traumatic brain injury. |
| NCT00105040 | Phase 2 | Completed | 87 | Randomised placebo-controlled study of cognitive/neuropsychological effects of adjunctive levetiracetam in children with refractory partial-onset seizures. |
| NCT00203216 | N/A | Completed | 31 | Open-label trial of levetiracetam for migraine prophylaxis, with or without visual aura. |
| NCT07336992 | Phase 3 | Not yet recruiting | 580 | Randomised placebo-controlled trial of prophylactic levetiracetam for functional outcome after intracerebral haemorrhage. |
| NCT04277936 | Phase 2 | Terminated (enrolment n=1) | 1 | Same hippocampal-hyperactivity/psychosis mechanism study as NCT04559529; terminated early. |
None of the above trials directly evaluate levetiracetam in a visual/photosensitive epilepsy population.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32385134 | 2020 | RCT | Pediatrics | Levetiracetam vs phenobarbital for neonatal seizures — randomised comparison of efficacy and safety. |
| 30487494 | 2018 | RCT | Mymensingh Med J | Randomised comparison of phenobarbital and levetiracetam efficacy/tolerability in childhood epilepsy. |
| 38678766 | 2024 | Open-label RCT | Seizure | Phenytoin vs levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome. |
| 34286461 | 2022 | Systematic Review/Meta-analysis | Neurocritical Care | Levetiracetam for seizure prophylaxis in ICH, TBI, neurosurgery and SAH — efficacy, dosing and adverse events remain unclear. |
| 37378757 | 2023 | Network Meta-analysis | J Neurology | Comparative efficacy/safety of antiseizure medications (including levetiracetam) for idiopathic generalised epilepsies. |
| 40450767 | 2025 | Systematic Review/Meta-analysis | Epilepsy & Behavior | Levetiracetam for myoclonic seizures in idiopathic generalised epilepsy, including juvenile myoclonic epilepsy. |
| 35538830 | 2023 | Meta-analysis | CNS Neurol Disord Drug Targets | Safety/effectiveness comparison of levetiracetam vs phenytoin in paediatric status epilepticus. |
| 36209676 | 2022 | Systematic Review/Network Meta-analysis | Seizure | Treatment options, including levetiracetam, for benzodiazepine-resistant status epilepticus. |
| 21936590 | 2011 | Review | CNS Drugs | Overview of levetiracetam’s approved indications and clinical profile in epilepsy (“Spotlight” review). |
| 35976303 | 2022 | Review | Arq Neuropsiquiatr | General review of status epilepticus diagnosis, monitoring and treatment. |
All identified literature addresses levetiracetam in general epilepsy/status epilepticus contexts; none specifically studies visual or photosensitive epilepsy.
Australia Market Information
Levetiracetam is currently not marketed in Australia under this evidence pack, with 0 ARTG entries recorded. No product listing, dosage form, or approved-indication text is available to summarise.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug-drug interaction data were retrievable for this evidence pack (TFDA/TGA labelling data gap — DG001, Blocking severity — must be resolved before any S1 safety pre-screen can proceed).
Conclusion and Next Steps
Decision: Research Question (Decision Stage S1)
Rationale: The mechanistic link between levetiracetam’s SV2A-mediated anti-hyperexcitability action and visual epilepsy’s cortical hyperexcitability is biologically plausible, but every identified trial and publication addresses general epilepsy, status epilepticus, or neonatal seizures rather than visual/photosensitive epilepsy specifically — there is no direct clinical evidence for this indication.
To proceed, the following is needed:
- TGA-approved Product Information — key warnings, contraindications, and drug interaction data (Blocking gap, DG001)
- Confirmed mechanism-of-action detail from DrugBank (High-priority gap, DG002)
- A trial or case series enrolling patients specifically diagnosed with visual/photosensitive epilepsy
- Formal ARTG registration status confirmation, since the drug is currently not marketed in Australia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.